Community/Retail

Approximately 50 million individuals have reported symptoms of acne vulgaris, a chronic inflammation of the skin consisting of whiteheads, blackheads, papules, pustules, or nodules.

New data suggests certain hospitalized CAP patients treated initially with oral antibiotics may not have worse outcomes compared to those initially treated with IV antibiotics.

Although it's difficult to determine exactly how many patients experience opioid-induced constipation, the large quantities of prescribed opioids in circulation create widespread potential for this bothersome adverse effect.

The opioid overdose death toll has been steadily increasing for more than a decade, making it a leading cause of accidental death in the United States.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacists can help prevent OIC.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses counseling points for OIC patients.

Jeffrey Gudin, MD, outlines the steps pharmacists should take to reduce opioid-induced constipation.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses the latest advancements in OIC treatment.

Meijer has announced that it is unveiling a Heritage Center rich with company history from its founder Hendrik Meijer's first arrival in the United States through the retailer's most recent innovations and expansions.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses potential adverse effects associated with naloxone.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacy-based OIC care differs from other settings.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system pharmacists can assess patients' risk for opioid overdose.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses OTC recommendations for OIC symptoms.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how often pharmacists work with OIC patients.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses what pharmacists should tell patients about administering naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses key stakeholders involved in developing and implementing outpatient naloxone policies.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system and community pharmacists can work together to provide naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses prices of naloxone products.

Jeffrey Gudin, MD, describes the impact of opioid-induced constipation on patients taking opioids.

The FDA has approved Novartis's etanercept-szzs (Erelzi), a biosimilar to Amgen's etanercept (Enbrel), for the treatment of several inflammatory diseases.

Today, Janet Woodcock, MD, Director, Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) delivered a keynote address at Leading on Biosimilars: The 2016 GPhA Biosimilars Council Conference.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses where fiber supplementation fits into OIC care.

CVS Health has announced the rollout of Project Health, its annual free health services campaign, at select CVS Pharmacy locations in 10 multicultural communities across the country.

There are many misconceptions surrounding pain management, especially when it comes to opioids with abuse-deterrent properties.

J. David Haddox, DDS, MD, describes how clinicians can determine whether an opioid has abuse-deterrent properties.

J. David Haddox, DDS, MD, describes the pharmacist's role in deterring opioid abuse.

The answer may surprise you.

J. David Haddox, DDS, MD, describes the most common method of opioid abuse.